PMID- 11897645
OWN - NLM
STAT- MEDLINE
DCOM- 20020417
LR  - 20131121
IS  - 1073-449X (Print)
IS  - 1073-449X (Linking)
VI  - 165
IP  - 6
DP  - 2002 Mar 15
TI  - Human leukocyte antigen Class II amino acid epitopes: susceptibility and 
      progression markers for beryllium hypersensitivity.
PG  - 788-94
AB  - Chronic beryllium disease (CBD) is a hypersensitivity granulomatosis 
      characterized by beryllium hypersensitivity (BH) and mediated by CD4+ T cells. 
      However, all individuals with BH may not develop CBD. To examine the role of the 
      three different human leukocyte antigen (HLA) Class II isotypes in BH with (CBD) 
      and without clinical disease (BHWCD), we performed DNA-based typing of HLA-DPB1, 
      HLA-DQB1, and HLA-DRB1 loci on 55 subjects with BH (25 with established CBD and 
      30 with BHWCD), and compared this with the results for 82 beryllium-exposed 
      workers with no evidence of BH. The allele distribution was utilized to identify 
      candidate amino acid epitopes that differed between the study groups. 
      HLA-DPB1-E69 was the most important marker for BH, and did not differentiate 
      BHWCD from CBD. A significant association with CBD was observed with HLA-DQB1-G86 
      (p(corr) < 0.04), and HLA-DRB1-S11 was significantly increased in CBD as compared 
      with BHWCD (p < 0.03). These observations suggest that HLA-DPB1-E69 is a marker 
      for susceptibility to BH and not just a progression marker for CBD. In addition, 
      HLA amino acid epitopes on HLA-DRB1 and -DQB1, in concert with or independently 
      of HLA-DPB1-E69, may be associated with progression to CBD.
FAU - Rossman, Milton D
AU  - Rossman MD
AD  - Department of Medicine, University of Pennsylvania School of Medicine, 
      Philadelphia, Pennsylvania, USA. rossmanm@mail.med.upenn.edu
FAU - Stubbs, Jose
AU  - Stubbs J
FAU - Lee, Chung Wha
AU  - Lee CW
FAU - Argyris, Elias
AU  - Argyris E
FAU - Magira, Eleni
AU  - Magira E
FAU - Monos, Dimitri
AU  - Monos D
LA  - eng
GR  - HL-48210/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Respir Crit Care Med
JT  - American journal of respiratory and critical care medicine
JID - 9421642
RN  - 0 (Amino Acids)
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-D Antigens)
RN  - OW5102UV6N (Beryllium)
SB  - IM
MH  - Amino Acids/genetics
MH  - Berylliosis/*genetics/prevention & control
MH  - Beryllium/*immunology
MH  - Case-Control Studies
MH  - Epitope Mapping
MH  - Genetic Markers
MH  - Genetic Testing/methods
MH  - HLA-D Antigens/*analysis/genetics
MH  - Humans
MH  - Hypersensitivity, Delayed/*chemically induced/*genetics/prevention & control
EDAT- 2002/03/19 10:00
MHDA- 2002/04/18 10:01
CRDT- 2002/03/19 10:00
PHST- 2002/03/19 10:00 [pubmed]
PHST- 2002/04/18 10:01 [medline]
PHST- 2002/03/19 10:00 [entrez]
AID - 10.1164/ajrccm.165.6.2104002 [doi]
PST - ppublish
SO  - Am J Respir Crit Care Med. 2002 Mar 15;165(6):788-94. doi: 
      10.1164/ajrccm.165.6.2104002.